摘要
目的:比较分析肿瘤热休克蛋白70(HSP70)与IL-2对小鼠肝癌移植模型的治疗作用,评价HSP70的疗效,为应用HSP70治疗人类恶性肿瘤提供有重要参考价值的实验依据。方法:细胞培养、蛋白质纯化技术、电泳技术、Westernblot法、动物实验等。结果:IL-2及HSP70对小鼠肝癌移植模型均有治疗作用,其中IL-210万U、HSP7010μg效果最佳,IL-25万U及HSP705μg有部分治疗作用,10万U的IL-2与5μgHSP70治疗效果相当,HSP7010μg治疗后有40％小鼠移植肿瘤全部消退,长期生存790d,与对照组及其他各组相比,差异具有显著性(P<0.01,P<0.05)。结论:HSP70具有良好的抗肿瘤免疫活性,其疗效明显优于IL-2,本研究对于应用HSP70治疗人类的恶性肿瘤有十分重要的借鉴意义。
AIM:To compare and analyze the therapeutic effect of tumorderived heat shock protein 70 and globally accepted interleukin-2, to evaluate the anti-tumor capacity of HSP70, and to provide significant information for HSP70 administration to treat human cancers. METHODS:Cell Culture, techniques for protein extraction and purification, SDS-PAGE, Western-blot and animal experiment were used in this study. RESULTS:Both IL-2 and HSP70 showed therapeutic effect in tumor-bearing mice. The best effect was observed in 100 000 U IL-2 and 10 pg HSP70 administrations, and partial efficacy was found in 50 000 U IL-2 and 5 μg HSP70 administrations. The effect of 100 000 U IL-2 was nearly as good as that of 5 μg HSP70. About 40 % mice receiving HSP70 10 μg administration survived over 90 days, the average survival period of this group was over 56.8 days, whereas the control group was 17.3 days, IL-2 50 000 group, 26.3 days, IL-2 100 000 group, 36.6 days, and 5 μg HSP70 group, 27.7 days. Significant difference was found (P<0.05) when compared with the HSP70 10 μg group and control group. CONCLUSION:HSP70 has a specific anti-tumor effect and obviously exceeded IL-2. Those data provide significant information for the treatment of human cancers.
出处
《世界华人消化杂志》
CAS
2003年第4期415-418,共4页
World Chinese Journal of Digestology
